RX RXRX Recursion Pharmaceuticals, Inc. Class A Common Stock Loading... : Bullish and Bearish Analyst Opinions

Speaker presents this as a top pick with bullish catalysts (clinical signals, pipeline, chart), no personal position stated.

Author expresses a general like for RXRX in a biotech bull run context but does not state a position or explicit forward call.

The author shares their favorite biotech stocks with AI-driven drug discovery and gene editing platforms but frames them as personal favorites without an explicit forward-looking position or trade call.

Avoid RXRX — speaker explicitly rejected it after due diligence, citing inferior fundamentals versus ABCL and warning that buyers will suffer consequences; implicit strong caution against entry.

Speaker states personal due diligence on RXRX was unsatisfactory, expressing skepticism without a specific deterioration mechanism or trade direction.

The author discloses a numbered portfolio of 11 current long positions by size and a separate focus list of 18 tickers for watchlist monitoring, expressing gratitude to followers for supporting his full-time trading career dream.

Watch RXRX for vertical AI biotech; NVIDIA's exit reduces near-term catalyst but platform persists.

One detailed comment (+5) notes RXRX has short interest 37% of float, days to cover 10.6, and institutional ownership 56% – a setup that could produce a squeeze if volume and a catalyst appear. While only a single comment, the data‑driven analysis provides a credible basis for monitoring. The community may not have full consensus, but the metrics are compelling. Place RXRX on watchlist; initiate a small long position or buy calls only if high volume and a clear catalyst (e.g., news, breakout above resistance) confirm the squeeze potential. Risks: Squeeze may not materialize; high short interest can also reflect fundamental weakness. No other comments corroborate the thesis.

These companies are either losing too much money in a tough tape, had bad quarters, failed to deliver on big promises, or are trading like meme stocks. In a macro environment threatened by inflation and oil shocks, the market has zero tolerance for cash-burning, speculative companies. Capital will aggressively rotate out of unprofitable tech and biotech into companies with real earnings and strong balance sheets. AVOID. Do not buy the dip on cash-burning or speculative stocks in a hostile, inflation-wary market. A sudden drop in interest rates or a rapid resolution to geopolitical conflicts could spark a risk-on rally, causing these heavily shorted or beaten-down names to squeeze higher.